First SGLT2 inhibitor, canagliflozin, approved to treat diabetic kidney disease in UK

Canagliflozin, as an add-on to standard care, has been licensed to slow the progression of diabetic kidney disease in patients with type II diabetes. Patients with eGFR 45 to <60ml/min and those eGFR 30ml/min to <45ml/min & albuminuria can be initiated on canagliflozin 100mg.


Monthly Index of Medical Specialities